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Abstract
Background:
Anti-epileptic drugs are known to be teratogenic, yet many women do need to continue the anti-epileptic
drug use during pregnancy.
Objectives:
To perform an economic evaluation of the anti-epileptic drug choice in young women who potentially wish to
become pregnant. In particular, to estimate the impact of teratogenicity on the costs per quality adjusted life
year (QALY).
Methods:
A decision-tree model is used to calculate the costs per QALY, taking into account the malformation risk in
offspring due to the exposure to carbamazepine, lamotrigine or valproic acid, based on the European birth
cohort of 2007. Probabilistic sensitivity analyses were performed using Monte Carlo simulation.
Results:
Valproic acid is dominated by carbamazepine after rank ordering on costs. The incremental cost-
effectiveness of lamotrigine vs carbamazepine was estimated at E175,534 per QALY. Although valproic
acid was dominated by carbamazepine in terms of costs and related effects, it is clinically relevant to
compare lamotrigine with valproic acid. In particular, treatment options are dependent on several individual
and clinical characteristics and these agents are therefore not always considered as interchangeable for all
specified populations. The incremental cost-effectiveness for lamotrigine vs valproic acid was estimated at
E13,370 per QALY. With assuming a willingness to pay threshold of E50,000 per QALY, results from the
probabilistic analysis resulted in an acceptance level for lamotrigine vs carbamazepine and lamotrigine vs
valproic acid of 4% and 99%, respectively.
Conclusion:
Based on epidemiological data it is advised to whenever possible avoid valproic acid during pregnancy. Both
carbamazepine and lamotrigine are estimated to be cost-effective treatment options vs valproic acid if
focused on teratogenicity.
Introduction
Epilepsy is a chronic disease with an age-dependent increase in prevalence.
About 0.5% of all teenage girls are using anti-epileptic drugs1,2. A considerable
part of these girls are still using the same anti-epileptic drug when they wish to
become pregnant, as switching is not considered to be easy and stopping often
not an option. In pregnancy,3.3 per 1000 women are using anti-epileptic drugs





























































in the first trimester, the period in which risks for congen-
ital malformations occur3,4. Teratogenicity differs between
specific anti-epileptic drugs. Therefore, it is important for
the prescribers to already keep in mind potential future
wishes to become pregnant when choosing between anti-
epileptic therapies in younger girls.
Carbamazepine, valproic acid and lamotrigine are the
most used anti-epileptic drugs, both among pregnant and
non-pregnant women5,6. All three agents are first choice
options for partial epilepsy. However, in the case of gen-
eralized epilepsy only valproic acid presents as the drug of
first choice and both carbamazepine and lamotrigine are
second choice therapies7,8. This is despite the fact that a
recent Cochrane review could not find evidence to support
the belief that valproic acid is superior to carbamazepine in
preventing generalized tonic-clonic seizures9.
Valproic acid is a relatively cheap and very effective
anti-epileptic drug, which is already a successful treatment
option in epilepsy for over 40 years. However, it is associ-
ated with an increased risk for major congenital malforma-
tions compared to other anti-epileptic drugs10. Maternal
use increases the risk for spina bifida, cleft palate, hypo-
spadias, atrial septal defect, polydactyly and craniosynos-
tosis in the newborns. In contrast, carbamazepine has been
shown to be only associated with an increased risk for spina
bifida, with a risk even significantly lower than for valproic
acid11. Lamotrigine on the other hand is more expensive,
but up to now not associated to any specific
malformations5,12,13.
No information is yet available on the cost-effective-
ness of these safety issues in anti-epileptic treatments. In
society the willingness to pay for a healthy child is often
high and potentially difficult to compare to the willingness
to pay for an intervention which will add an extra year to
individuals’ life expectancies. ‘Interventions’ with a higher
willingness to pay are certainly not uncommon for eco-
nomic analyses considering safety risks (e.g., blood prod-
ucts)14. Also, the general willingness to pay to avoid health
losses is greater than the willingness to pay for health
gains15.
The aim of this study is to perform an economic eval-
uation for anti-epileptic drugs initiated in young women
with a potential wish to become, applying the societal per-
spective and focusing on safety in the offspring rather than




Based on the EUROCAT Antiepileptic Study Database the
prevalence for major congenital malformations in the
general population is 2.8%12. This prevalence increases
in the case of maternal carbamazepine (3.3%)11, lamotri-
gine (3.2%)5 or valproic acid (7.5%)10 exposures. The
decision tree for specific malformations associated with
choices in anti-epileptic drug use is presented in Figure
1. Some specific malformations are known to be increased
by these anti-epileptic drugs, however it does not fully
explain the total prevalence5,10–13. The unexplained part
is defined as ‘not otherwise specified’ (NOS).
Health gains
For all associated malformation sub-groups we estimated
the quality-of-life and the life expectancy of the offspring
based on the published literature (Table 1)16–31. For our
‘rest group’ of NOS malformations it was not possible to
find any reference. Therefore, we took the quality-of-life of
pregnancy outcomes with an extreme low birthweight as a
proxy (0.97) in the base case analysis23. This assumption
was varied in both univariate (to see how sensitive the
analysis is for this parameter) and probabilistic sensitivity
analysis.
Costs
We assumed lifetime use of anti-epileptic drugs starting at
age 15. Based on European life tables, we estimated the
lifetime costs for the three anti-epileptic drugs in 2010
Euros: carbamazepine (dose 1000mg/day) atE2707, lamo-
trigine (dose 300mg/day) at E11,329 and valproic acid
(dose 1500mg/day) at E36948,32. These values were
based on Dutch prices.
Lifetime costs for each of the specific malformations
were estimated based on published literature. All costs
are presented for 2010 Euros. If costs were originally cal-
culated in another currency or from another year we used
the historical exchange rate and deflator33,34. Table 1 gives
an overview of all lifetime costs per malformation sub-
group.
Incremental cost-effectiveness and cost-utility
analysis
In the incremental cost-effectiveness analysis the net costs
per quality adjusted life year (QALY) were calculated com-
paring the three anti-epileptic drugs, by dividing the dif-
ference in the ‘total net lifetime costs’ by the sum of the
differences in, respectively, the life years lost and the qual-
ity-of-life lost (presented in Table 2). All costs and health
gains were discounted following the Dutch guidelines for
conducting pharmacoeconomic studies with 4% and 1.5%,
respectively35.
The analysis is performed based on the European Union
(27 countries) birth cohort of 2007 which consist of
5,285,057 live births (49% male) and the average life
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expectancy at birth of this cohort at 79.2 years32. As the
prevalence of first trimester exposure to anti-epileptic
drugs is 3.3 per 1000, 17,441 pregnancies of the EU
2007 birth cohort would be expected to be first trimester
exposed3,4. We calculated the total costs and effects based
on assuming that all 17,441 women used carbamazepine,
lamotrigine or valproic acid. For our model, we assumed
equal effectiveness of the three drugs in all women. We
know that in practice this is not the case due to differences
in severity, type of epilepsy and interpersonal differences.
However, it is difficult to account for such hetereogeneity
and all three drugs have proven to be effective in the most
common types of epilepsy7,9. Therefore, incremental cost-
effectiveness results were solely driven by safety
differences.
Probabilistic analysis was conducted to account for
uncertainty around the lifetime costs of themalformations,
the prevalence of the specific malformations and the
QALYs per treatment option. Cost-effectiveness planes
were constructed based on Monte Carlo simulation
(10,000 replicates) to test the robustness of the health
economic outcomes. Additionally, cost-effectiveness
acceptability curves were derived to estimate the probabil-
ity of acceptance with varying willingness-to-pay
thresholds.
Results
The total number of malformed pregnancy outcomes, life
years and quality-of-life lost estimated for the 17,441 preg-
nancies analyzed are shown in Table 2. The general risk for
malformations is 2.8%, which would result in 493 mal-
formed pregnancy outcomes. This background risk is pre-
sented in the first column. The subsequent analyses are
based on the incremental estimates compared to the back-
ground risk.
If the three drugs are rank ordered on costs, one can
directly see that valproic acid is dominated (higher costs
and more quality-of-life losses than carbamazepine). From
an economic point of view, due to the dominance, valproic
acid would not be considered as a first choice treatment
option. However, as the indications for the three drugs
are not exactly the same and, therefore, not 100%
VPA exposed pregnancy
0.005 ASD









0.001 spina bifida0.033 malformed
0.967 non-malformed
LTG exposed pregnancy
0.032 NOS malformed0.032 malformed
0.968 non-malformed
NOS, not otherwise specified 
Figure 1. Decision tree showing the prevalence per specific malformation associated with valproic acid (VPA), carbamazepine (CBZ) and lamotrigine
(LTG)5,10,11.
Table 1. Discounted losses in quality-of-life and life years and the lifetime








Spina bifida 20.3 15.1 E138,964
Atrial Septal Defect 0.4 0 E6591
Cleft palate 1.3 0 E13,345
Hypospadias 0.8 0 E5890
Polydactyly 0 0 E893
Craniosynostosis 5.0 0 E14,990
NOS malformation 1.2 4.9 E94,052
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interchangeable, the incremental cost-effectiveness is
calculated for both lamotrigine vs carbamazepine and
lamotrigine vs valproic acid. The incremental cost-
effectiveness of lamotrigine vs carbamazepine and lamo-
trigine vs valproic acid were estimated at E175,534 and
E13,370 per QALY, respectively.
Table 2 shows that the anti-epileptic drug price is the
main driver of the incremental cost-effectiveness. In par-
ticular, this is related to the nature of use of these agents,
which is basically lifetime. The prices of carbamazepine
and valproic acid are quite stable over recent years.
With only limited sources for quality-of-life data on
specified and NOS malformations, sensitivity analysis
was directed at this. Notably, the outcomes were quite
robust. In particular, results remained essentially
unchanged with increasing or decreasing the estimated
losses in quality-of-life and life years with 50%
(E170,168–184,074 per QALY for lamotrigine vs carba-
mazepine and E11,685–14,793 per QALY for lamotrigine
vs valproic acid).
In Figure 2 the incremental cost-effectiveness planes
are presented for both lamotrigine vs carbamazepine and
lamotrigine vs valproic acid. All estimates for the compar-
ison of lamotrigine vs carbamazepine are located in the
northern quadrants, with the highest density in the north-
east. For the comparison of lamotrigine vs valproic acid all
estimates are located in the northeast quadrant, indicating
a better quality-of-life for additional costs.
As there is no formal willingness-to-pay threshold in
the Netherlands, cost-effectiveness acceptability curves
are calculated to estimate the probability of acceptance
for different willingness-to-pay thresholds in Figure 336.
Arbitrarily considering a willingness-to-pay threshold of
E50,000 per QALY, the probability of the acceptance
for lamotrigine vs carbamazepine and lamotrigine vs val-
proic acid were estimated at 4% and 99%, respectively.
The median incremental cost-effectiveness is estimated
at E173,353 per QALY for lamotrigine vs carbamazepine
and atE13,548 per QALY for lamotrigine vs valproic acid.
Discussion
Carbamazepine, lamotrigine and valproic acid are all first-
choice therapy options in the treatment of partial epilepsy.
In general, valproic acid is widely used, but from a health
economic point of view it would not be a first-choice ther-
apy option for women with a potential wish to become
pregnant with partial epilepsy as it is dominated by carba-
mazepine. Lamotrigine results in better quality-of-life out-
comes in the offspring at higher costs of E175,534 per
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Figure 2. Incremental cost-effectiveness planes for lamotrgine vs carbamazepine and vs valproic acid: comparing differences (delta) in costs and effects.
Table 2. Total net costs (4% discount rate) and health effects (1.5% discount rate) for carbamazepine, lamotrigine and valproic acid for the European birth
cohort of 2007 (17,441 exposed births).
Background risk Carbamazepine Lamotrigine Valproic acid
















Life years lost 2417 3104 2774 6110
Quality of life lost 591 1192 679 3752
QALYs lost 3008 4296 3453 9862
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However, we should keep in mind that economic evalua-
tions based on solely safety outcomes of drugs for the next
generation could be comparable to other economic evalu-
ations in which safety is important, for example, blood
transfusions. In this field, interventions are still imple-
mented with a net cost of several millions per QALY14.
Our results are conservative. For example, we do not
take into account that these drug costs cover all costs for
the mother, independent of the number of children. If a
woman delivers two children, the drug costs can crudely be
divided by two and cost-effectiveness improves drastically.
Additionally, we took into account the lifetime drug costs
starting at the age of 15; cost-effectiveness would improve
if only drug costs during fertile years would be counted.
In the analyses, we assumed that the three drugs are
equally effective in all women who require these anti-
epileptic drugs. This does not necessarily correspond
with the daily practice situation as, for example, not all
women will receive the standard dose. Therefore, in daily
practice the therapy choice should be made on an individ-
ual level based on effectiveness which is dependent on
several factors, with a pharmacologically uncontrolled
woman probably being the most expensive. Therefore,
despite the dominance, valproic acid is not to be ruled
out as an alternative treatment option in clinical practice
as it reflects a very effective drug with a lot of treatment
experience. In particular, it is known that there is a sub-
group of women that only successfully respond to valproic
acid and, for some specific types of epilepsy, valproic acid
might be considered as the best or even the only treatment
option. Considering the exact indications, lamotrigine
may be considered more comparable to valproic acid
than to carbamazepine for some specific types of epilepsy.
Therefore, we also calculated the incremental cost-effec-
tiveness ratio for lamotrigine vs valproic acid, resulting in
E13,370 per QALY, which can be conceived as a favorable
cost-effectiveness ratio.
We did not include effects on the cognitive develop-
ment of the children. Valproic acid exposure during
pregnancy has been associated with a lower IQ in the
child37. No evidence exists for a comparable cognitive
effect for carbamazepine or lamotrigine. Notably, as lamo-
trigine is a newer drug there is no data yet available on the
school performance of children exposed to lamotrigine.
Obviously, lower IQ could possibly result in less contribu-
tion to society over lifetime (e.g., production losses). The
same holds true for some of the malformations (e.g., spina
bifida). Potential production losses and related losses in tax
contribution in the next generation are nicely described in
the field of assisted reproduction38. Further work could be
directed to formally include these aspects in our model
design.
Notably, only limited evidence exists on the parameter
assumptions for the economic evaluation. The available
studies presenting quality-of-life and life expectancy data
applied various methods, which are sometimes difficult to
compare. Also, cost data were derived from several studies
performed all over the world. Apart from acknowledging
this limitation and justifying these assumptions as the best
there are, we feel that this analysis also nicely illustrates
one of the major problems in performing economic evalu-
ations in the field of teratology research. For example, the
estimates for the lifetime costs for any malformation are
based on a study which took into account only 16 different
malformations (accounting for 33% of the prevalence of
all major malformations)12,31.
Ideally most assumptions are derived from clinical trial
data, however these study designs are unethical to use for
estimating teratogenicity of drugs. Therefore, information
has to be derived from observational studies. For economic
evaluations information is required on the association
between a specific drug and a specific malformation.
Cohort studies often do not have enough power to provide
a precise estimate. Case-control studies do provide such
information but are generally more difficult to integrate
in the economic analyses.
Pharmacoeconomic analyses are not common in the
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willingness to pay (per QALY)
Figure 3. Cost-effectiveness acceptability curves for lamotrigine vs carbamazepine and lamotrigine vs valproic acid.
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choices, taking into account potential safety risks for the
offspring. From the current analysis, it becomes clear that
there are still a lot of important methodological issues left
that need to be discussed further. In this paper the analysis
is performed for a specific birth cohort. Analyses taking
into account the risk for malformations need to be based
on large numbers as the prevalence of major malformations
is only 3% of all births, which correspondingly could
require economic analysis based on multiple cohorts.
Furthermore, an imminent question relates to the willing-
ness to pay threshold for avoiding teratogenic risks in off-
spring; in particular, is this comparable to that for drugs
improving the quality-of-life of the actual consumer?
Conclusions
In short, based on epidemiological data it is recommended
to avoid valproic acid exposure during pregnancy due to a
higher risk of teratogenicity39. Also from a health eco-
nomic point of view, the use of the teratogenic anti-
epileptic drugs carbamazepine and lamotrigine is estimated
to be cost-saving and cost-effective, respectively, if com-
pared to valproic acid. This definitely holds true if analyses
investigating teratogenicity are interpreted as interven-
tions to enhance safety14. The cost-effectiveness of such
interventions directed at safety and averting losses in qual-
ity-of-life are generally interpreted differently with much
higher willingness to pay being documented as for inter-
ventions with superior effectiveness. Yet, the best treat-
ment option should in the end be made on an individual
tailor-made basis and would not only rely on health-
economic outcomes. The latter merely serve to provide
general guidance on the overall level.
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